1 tion in infarct size (assessed as plasma creatine kinase and troponin I area under the curve over 3 days). The main secondary endpoint will be infarct size normalized to the myocardium at risk (expressed by the myocardial salvage index assessed by cardiac magnetic resonance). The study is being financed under an EU-FP7 grant and conducted under the auspices of the MITOCARE research consortium, which includes experts from clinical and basic research centers, as well as commercial enterprises, throughout Europe. Results from this study will contribute to a better understanding of the complex pathophysiology underlying myocardial injury after STEMI. The present paper describes the rationale, design and the methods of the trial. 
Introduction
Current treatment of acute ST-elevation myocardial infarction (STEMI) by reperfusion using percutaneous coronary intervention (PCI) or thrombolysis provides tremendous clinical benefits by reducing infarct size and mortality following cardiac ischemia. However, reperfusion also induces considerable cell death. This process is called reperfusion injury and is believed to ac-count for about 50% of the remaining infarction [1] . The continuing high rates of mortality ( ϳ 10%) and heart failure after acute myocardial infarction (AMI; ϳ 18%) [2] emphasize the need for improved strategies to limit reperfusion injury in order to further improve clinical outcomes.
Several strategies for the reduction in reperfusion injury, such as post-conditioning [3] , cyclosporine A [4] and FX06 [5] , have been studied in phase II trials in patients undergoing PCI. Although these therapies have demonstrated the potential to reduce infarct size measured by some cardiac parameters, results were not consistent for all biomarkers or cardiac magnetic resonance (CMR) measurements.
In the clinical trial with cyclosporine A, a significant 40% reduction in the plasma creatine kinase (CK) area under the curve (AUC) from 0 to 48 h was observed together with a 20% reduction in infarct size assessed by MRI [4] . However, the effect on plasma troponin I, which is considered a more specific marker for myocardial damage than CK, was not statistically significant. Similarly, FX06 resulted in a significant 58% reduction in the necrotic core zone assessed by MRI, but no significant change in late gadolinium enhancement (LGE), mean troponin I plasma levels or the CK myocardial band activity [5] . The efficacy of post-conditioning remains controversial despite positive results in early studies [3, [6] [7] [8] [9] [10] . Subsequent trials did not report a reduction in infarct size, but rather found that post-conditioning might have potential harmful effects [11, 12] . TRO40303 (3,5-seco-4-nor-cholestan-5-one oxime-3-ol), a mitochondrial permeability transition pore (mPTP) modulator, was identified in a cell-based assay designed to identify molecules that maintain survival of trophic factor-deprived motor neurons [13] . It binds specifically to the mitochondrial translocator protein at the cholesterol site and has the potential to decrease mitochondrialmediated cell death.
TRO40303 has been shown to reduce infarct size in preclinical animal models [14] . It specifically targets reperfusion-related events, delaying mPTP opening triggered by hypoxia reoxygenation in cardiomyocytes in vitro and reducing the release of apoptosis-inducing factor into the cytosol after in vivo ischemia reperfusion [14] . Since TRO40303 targets specific reperfusion events, it has the potential to prevent or limit myocardial reperfusion injury, evolution to heart failure and the subsequent need for regenerative therapies.
The MITOCARE consortium, which began in January 2011, is a group of experts from 9 clinical centers, 3 basic research centers and 4 small and medium-sized enterprises, for a total of 16 teams throughout Europe specializing in clinical and basic research, biomarkers, imaging and informatics. This EU-FP7 (EU-7th Framework Program)-funded consortium focuses its expertise on the problem of cardiac ischemia reperfusion injury.
Study Rationale
This trial seeks to evaluate the efficacy and safety of a new drug, TRO40303, in patients presenting early with a STEMI, the period when reperfusion therapy has the greatest benefit. TRO40303 targets the mPTP, a highly promising target for the prevention of reperfusion injury [15, 16] . The primary outcome measure will be reduction in infarct size, which is known to be an important surrogate endpoint for morbidity and mortality following AMI [17, 18] .
In the present phase II trial, TRO40303 or placebo will be given, as an adjunct to current standard cardiac care, to patients undergoing primary PCI to treat STEMI. Results from this study will contribute to a better understanding of the complex pathophysiology underlying myocardial injury after STEMI.
Study Objectives
The objective of the study is to assess the safety and efficacy of TRO40303, which is administered just before balloon inflation or thromboaspiration during PCI for the limitation of infarct size in patients treated for STEMI. Comparative efficacy between TRO40303-and placebo-treated patients will be assessed using cardiac biomarkers and cardiac imaging. The co-primary measures of efficacy will be infarct size expressed as AUC for CK and AUC for troponin I (used for sample size calculation) over 3 days.
The main secondary outcome measure will be infarct size normalized to the myocardium at risk, expressed as 'myocardial salvage index', evaluated by CMR. Additional secondary outcome measures to be compared between TRO40303-and placebo-treated groups include: left ventricular function after PCI measured by CMR (days [3] [4] [5] and echocardiography (days 3-5 and 30); ST-segment decrease after PCI (ECG before PCI compared to an ECG performed 1 h after stenting); magnitude of microvascular obstruction measured by CMR and transmural extension of the infarct measured by CMR.
A subgroup analysis of infarct size (evaluated by cardiac biomarkers and cardiac imaging) will be conducted according to the culprit vessel. In addition, patients will be classified according to Killip class and GRACE score.
Safety will be assessed at baseline, and 3 and 30 days after PCI. Measures include physical examination (clinical symptoms and weight), vital signs (blood pressure and heart rate), serum creatinine, triglycerides, urea, blood glucose, electrolytes, serum bilirubin, ␥ -glutamyltransferase, alkaline phosphatase, amino transferase, alanine amino transferase and high/low density lipoprotein cholesterol, as well as hematology and blood coagulation tests. Cumulative incidence of major adverse events occurring during the first 48 h after reperfusion, including death, heart failure, AMI, stroke, recurrent ischemia, the need for repeat revascularization, renal, hepatic or vascular complications, and bleeding, will be assessed. Cardiac and non-cardiac events occurring within the initial 30 days will be recorded.
Additional biomarker measures are listed in table 1 . These markers will be used to assess factors for potential confounding influence or prognostic value for infarct size, future progression to heart failure, risk stratification, mechanism of cardioprotection and variability of response. Biomarker assays are centralized. In addition, a biobank of patients' plasma, serum and RNA will be established for further investigations.
Study Design
MITOCARE is a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIa, proofof-concept study in patients with large STEMI undergoing primary PCI, where TRO40303 or placebo will be administered as a single intravenous bolus prior to the reperfusion by angioplasty.
Patient Population
The study will be conducted in 9 study centers across 4 European countries. A planned total of 180 patients will be assigned 1: 1 to receive either TRO40303 or placebo. The study population includes patients 1 18 years of age with a first-time AMI. Patient inclusion and exclusion criteria are listed in table 2 .
Study Interventions
Eligible patients will undergo primary PCI and receive concomitant medications according to the current standard of care. After coronary angiography, but just before balloon inflation or thromboaspiration, patients who meet the enrolment criteria will be randomized to receive either placebo or TRO40303 ( fig. 1 ). Randomization is ensured by taking the treatment units in ascending and consecutive order in each infarction stratum (anterior/ posterior as determined on ECG).
Patients will receive an intravenous slow-bolus (35 ml/ min) injection of TRO40303, 6 mg/kg, or an equivalent volume of placebo, a maximum of 15 min (ideally ! 5 min) before balloon inflation and stenting. Patients will subsequently undergo in-or outpatient CMR and echocardiography between days 3 (ideally) and 5. Follow-up safety assessment and echocardiography will be performed 30 days after PCI. Patients will remain in hospital as long as medically indicated.
Since this clinical trial is being conducted within the context of an acute medical emergency, traditional case report forms (CRF) will be replaced with a new electronic version (eCRF) available on portable devices (iPad TM ) and adapted for an emergency setting. This will allow for greater ease of data collection and reduce the possibility of errors in study monitoring.
Cardiac MRI
Cardiac imaging has been shown to allow for assessment of infarct size and heart function in acute ischemic heart disease [19] . CMR using LGE is currently considered the clinical method of choice for detailed depiction of myocardial infarction [20, 21] . Clinically, imaging techniques are not systematically applied, primarily due to cost limitations; however, they are very useful in establishing the efficacy of new cardioprotective agents.
Infarct size in man is influenced by the duration of ischemia and by the size of the myocardium at risk [22] , which is dependent on the site of the coronary occlusion. CMR has been shown to enable quantification of the myocardium at risk using T2-weighted CMR [23] . This technique has also been clinically validated against myocardial perfusion single-photon emission computed tomography and shown to depict the myocardium at risk up to 1 week after the acute coronary event [24] . Furthermore, contrast-enhanced steady-state free precession has recently been shown to also enable depiction of the myocardium at risk 1 week after the acute event [25, 26] . The main secondary endpoint in this study is the infarct size normalized to the myocardium at risk, expressed as the myocardial salvage index. Use of this parameter measures the efficacy of treatment, but also provides data on patient variability and allows comparisons with preclinical data where infarct size is usually evaluated as the percentage of the area at risk.
Infarct size will be assessed from the LGE CMR images using a previously validated quantification method [27] . To avoid overestimation of infarct size by LGE CMR in the first days after the acute event [28, 29] , the CMR will be performed 3-5 days later. The myocardium at risk will be assessed either by T2-weighted imaging [24] or contrast-enhanced steady-state free precession imaging [25] . All image analysis will be performed by ImaCor AB (Lund, Sweden). The CMR imaging will be performed on whole-body MR scanners with cardiac applications used for standard clinical CMR.
Statistical Considerations
The sample size calculation was based on a standardized difference of 0.47, estimated from data in the study by Piot et al. [4] . Assuming a reduction of 35% in troponin I AUC, for a statistical power of 85% and a probability of type I error of 0.05 using a two-sided test, the sample size was computed to be 166 patients (83 per group), which has been rounded to 180.
Between-group comparisons of AUC for serum troponin I and CK release will be performed using O'Brien's method for multiple-endpoint testing. Comparisons of CMR data will be performed using an analysis of covariance mixed model. Centers and patients will be considered as random effects and treatment as a fixed effect. Time to PCI, area at risk and culprit artery will be used as covariates for these analyses. All analyses will be performed on the intent-to-treat and per-protocol populations.
For the safety analyses, a comparison of the incidence of cumulative adverse clinical events between treatment groups will be performed using Fisher's exact tests.
Trial Organization

Steering Committee
The clinical research steering committee is responsible for supervising the trial and shall provide advice to the project coordinator (Trophos) pertaining to key decisions for the good management of the clinical trial. This committee will also bear overall responsibility for the design, conduct and supervision of the study. It is responsible for reviewing the progress of the study at regular intervals to guarantee safety and trial integrity. The committee will also be responsible for providing clinical guidance on how to interpret the study protocol, study implementation and elucidation of results.
Data Management and Statistical Analysis
All data management-and statistical analysis-related tasks will be conducted by the Clinical Research Unit, Lariboisière Hospital, Paris, France, with the resultant outcome and safety data being continually provided to the independent drug safety monitoring firm. A new eCRF will be created by Mobile Health for use on the portable iPad device. CMR images will be transferred from the study centers to a central image database using a new software platform developed by the consortium. Images are automatically anonymized and scanned for inconsistencies before being electronically transferred. As soon as images are transferred, a quality assurance manager on call is notified via text message. Images can be reviewed on any web-enabled mobile device, allowing for direct and fast feedback to sites regarding image quality and potential deviations from imaging protocol, thus potentially minimizing the risk of missing patient data due to inadequate imaging.
Data Monitoring Committee
Two clinicians and a statistician will take part in a data monitoring committee, tasked with ensuring patient safety during the trial. The committee will regularly be provided with safety and efficacy data in a semi-blind way, as well as details of all serious adverse events.
Clinical Event Committee
The clinical events committee is made up of interventional and non-interventional cardiologists who are not participants in the study. It will be responsible for the adjudication of cardiovascular events based on review of CRF data, serious adverse event reports and source documents (hospital discharge summary, ECG and other supporting documents).
Safety and Ethics Monitoring Committee
The safety and ethics monitoring committee is in charge of ethics and personal data protection in the clinical trial. It is composed of a data protection specialist and an ethics specialist.
Clinical Implications
Previous data show that TRO40303 targets a key event that occurs at the time of reperfusion, namely mPTP opening, making this agent a promising option in reducing reperfusion injury. The MITOCARE project aims to provide in vivo validation of mPTP as a relevant target for the prevention of myocardial ischemia reperfusion injury and evidence that these mitochondrial processes are modifiable in humans. Effective reduction of reperfusion injury using TRO40303 should decrease the need for regenerative treatments, reduce the development of heart failure and, importantly, reduce mortality.
The MITOCARE project will help increase the understanding of the pathology and evolution of AMI by identifying and extensively analyzing patient-related confounding factors. Identification of new biomarkers will enhance the subsequent development of better tools for the diagnosis and follow-up of AMI.
In addition, clinical results will be compared to those in preclinical models of AMI in order to better refine the understanding of these models, including their utility and limitations for use in research on the pathophysiology of reperfusion injury and for testing potential therapies.
